Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600# Yishan Road, Shanghai, 200233, China.
Department of Radiology, University of Wisconsin-Madison, Room 7137, 1111 Highland Avenue, Madison, WI, 53705-2275, USA.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):132-150. doi: 10.1007/s00259-017-3839-5. Epub 2017 Oct 30.
Melanoma represents the most aggressive form of skin cancer, and its incidence continues to rise worldwide. F-FDG PET imaging has transformed diagnostic nuclear medicine and has become an essential component in the management of melanoma, but still has its drawbacks. With the rapid growth in the field of nuclear medicine and molecular imaging, a variety of promising probes that enable early diagnosis and detection of melanoma have been developed. The substantial preclinical success of melanin- and peptide-based probes has recently resulted in the translation of several radiotracers to clinical settings for noninvasive imaging and treatment of melanoma in humans. In this review, we focus on the latest developments in radiolabeled molecular imaging probes for melanoma in preclinical and clinical settings, and discuss the challenges and opportunities for future development.
黑色素瘤是最具侵袭性的皮肤癌，其发病率在全球范围内持续上升。氟代脱氧葡萄糖正电子发射断层扫描（F-FDG PET）成像改变了诊断核医学，并成为黑色素瘤治疗管理的重要组成部分，但仍存在其局限性。随着核医学和分子成像领域的快速发展，已经开发出多种有前途的探针，能够实现黑色素瘤的早期诊断和检测。黑色素和肽基探针的大量临床前成功，最近已将几种放射性示踪剂转化为临床应用，用于非侵入性成像和人类黑色素瘤的治疗。在这篇综述中，我们专注于临床前和临床环境中用于黑色素瘤的放射性标记分子成像探针的最新进展，并讨论了未来发展的挑战和机遇。
